Loading chart...
LLYLLY
$1,183.56Up 0.14 percent, +$1.67
As of Sep 25 at 4:00 PM ET
Key Stats
Market Cap$1054.885B
Volume (24h)1,420,896
Day's Range$1160.83-$1191.68
52-Week Range$716.08-$1292.65
About Eli Lilly & Co.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
- Website
- lilly.com
- Industry
- PHARMACEUTICAL PREPARATIONS
- Full-time Employees
- 50,000
- Headquarters
- INDIANAPOLIS
- IPO Date
- Jul 09, 1970
| 24 hours | 5 days | 1 month | YTD | 1 year | All time |
|---|---|---|---|---|---|
Up 0.14 percent | Up 1.60 percent | Down 0.49 percent | Up 9.61 percent | Up 63.35 percent | Up 1808.04 percent |
Latest LLY News
Positive
(opens in a new tab)
Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become
Neutral(opens in a new tab)
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
Positive
(opens in a new tab)
Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight
Neutral(opens in a new tab)
InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines
Neutral(opens in a new tab)
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
Positive
(opens in a new tab)
